WEIGHT & METABOLIC RESEARCH
A GHRH analog specifically studied for reducing deep abdominal (visceral) fat.
Tesamorelin is a GHRH analog studied specifically for reducing visceral adipose tissue (VAT)—the deep abdominal fat that surrounds internal organs and is strongly linked to insulin resistance and cardiovascular risk. It is FDA-approved for a specific clinical indication (HIV-associated lipodystrophy).
Included because it is FDA-approved (for a specific indication), works through a well-characterized GHRH-receptor mechanism, and has a defined clinical track record. It represents targeted, established metabolic research rather than broad weight-loss marketing.
Binds GHRH receptors on the pituitary, triggering natural GH and IGF-1 release.
Preferentially targets deep abdominal fat stores while, in studies, not reducing subcutaneous fat or muscle mass.
WHAT THE RESEARCH MEASURED
Findings describe study outcomes, not expected personal results.
Tesamorelin is FDA-approved for a specific clinical indication (HIV-associated lipodystrophy) and is not approved for general weight loss. Material offered here is sold and offered strictly for laboratory and research use.
